

	AVASTIN	LUCENTIS	EYLEA	Brolucizumab
Q3 2011	63%	37%	0%	
Q1 2012	57%	32%	11%	
Q2	58%	28%	14%	
Q3	53%	27%	20%	
Q4	48%	30%	21%	
Q1 2013	48%	29%	23%	
Q2	49%	28%	23%	
Q3	47%	27%	26%	
Q4	51%	28%	21%	
Q1 2014	50%	25%	24%	
Q2	50%	29%	21%	
Q3	48%	27%	25%	
Q4	45%	27%	28%	
Q1 2015	46%	22%	32%	
Q2	43%	25%	32%	
Q3	41%	24%	35%	
Q4	44%	21%	35%	
Q1 2016	45%	18%	36%	
Q2	44%	19%	37%	
Q3	45%	19%	36%	
Q4	43%	20%	37%	
Q1 2017	44%	19%	37%	
Q2	44%	17%	39%	
Q3	44%	18%	38%	
Q4*	45%	18%	37%	
Q1 2018	44%	20%	37%	
Q2	42%	19%	39%	
Q3	43%	20%	37%	
Q4	42%	20%	38%	
Q1 2019	41%	20%	39%	
Q2	42%	20%	38%	
Q3	40%	19%	41%	
Q4	44%	15%	39%	2%
Q1 2020	42%	15%	39%	4%
Q2	39%	18%	39%	4%
Q3	42%	14%	39%	5%
Q4	40%	15%	40%	5%
Q2 2021	39%	15%	42%	4%

Mylan v. Regeneron  
 IPR2021-00881  
 U.S. Pat. 9,254,338  
 Exhibit 2279